Predictive score for hepatocellular carcinoma after hepatitis B e antigen loss in patients treated with entecavir or tenofovir
- Lim, Tae Seop; Lee, Hyun Woong; Lee, Jung Il; Kim, In Hee; Lee, Chang Hun; Jang, Byoung Kuk; Chung, Woo Jin; Yim, Hyung Joon; Suh, Sang Jun; Seo, Yeon Seok; Lee, Han Ah; Yu, Jung Hwan; Lee, Jin-Woo; Kim, Sang Gyune; Kim, Young Seok; Park, Soo Young; Tak, Won Young; Kim, Soon Sun; Cheong, Jae Youn; Jeong, Soung Won; Jang, Jae Young; Rou, Woo Sun; Lee, Byung Seok; Kim, Seung Up; Korean Transient Elastography Study Group
- Issue Date
- hepatitis B; hepatitis B e antigen; hepatocellular carcinoma; risk prediction
- Journal of Viral Hepatitis, v.27, no.10, pp.1052 - 1060
- Journal Title
- Journal of Viral Hepatitis
- Start Page
- End Page
- The risk of developing hepatocellular carcinoma (HCC) after hepatitis B e antigen seroclearance (ESC) remains unclear. We established and validated a new risk prediction model for HCC development after ESC in patients with chronic hepatitis B (CHB) receiving antiviral therapy (AVT). Between 2006 and 2016, 769 patients (training cohort) and 1,061 patients (validation cohort) with CHB who experienced ESC during AVT using entecavir (ETV) or tenofovir disoproxil fumarate (TDF) were recruited. In the multivariate analysis, male sex (hazard ratio [HR] = 2.092; 95% confidence interval [CI] = 1.152-3.800), cirrhosis (HR = 5.141; 95% CI = 2.367-11.167) and fibrosis-4 index (FIB-4) of >3.25 (HR = 2.070; 95% CI = 1.184-3.620) were the independent risk factors for HCC development (all P < .05). Accordingly, a novel HCC-ESCAVT model was developed (1x[sex: male = 1, female = 0] + 3x(cirrhosis = 1, noncirrhosis = 0) + 1x(FIB-4: >3.25 = 1, <= 3.25 = 0). The cumulative risk for HCC development was significantly different among the risk groups based on the HCC-ESCAVT category (0-1, 2-4 and 5 for the low-, intermediate- and high-risk groups, respectively) (overall P < .001, log-rank test). The area under the receiver operating characteristic curve (AUC) for predicting HCC development 3, 5 and 10 years after ESC was 0.791, 0.771 and 0.790, respectively (all P < .05). The predictive value of the HCC-ESCAVT model was similar in the validation cohort (AUC = 0.802, 0.774 and 0.776 at 3, 5 and 10 years, respectively; all P < .05). Hence, we have developed and validated a new HCC-ESCAVT model for HCC development, which includes male sex, cirrhosis and FIB-4 of >3.25 as constituent variables.
- Files in This Item
- There are no files associated with this item.
- Appears in
- 2. Clinical Science > Department of Gastroenterology and Hepatology > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.